Sector News

MSD buys UK cancer drug discovery group IOmet

January 13, 2016
Life sciences

MSD has snapped up British drug discovery group IOmet, securing access to a new batch of preclinical cancer candidates to help stock up its early R&D pipeline.

The move sees Edinburgh, UK-based IOmet – which is focused on the development of innovative oncology medicines with a particular emphasis on cancer immunotherapy and metabolism – become a wholly-owned subsidiary of MSD (called Merck in the US).

The deal, financial terms of which were kept under wraps, adds a comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors to MSD’s pipeline.

IDO1 and TDO are key targets in the cancer immunotherapy field, as over-expression of these enzymes has been detected in a variety of cancers – including glioma, melanoma, lung, ovarian, and colorectal cancers – and is associated with poor prognosis and survival.

“Extensive preclinical evidence, and emerging clinical data, suggests that inhibition of IDO1 and/or TDO may synergise with, and help overcome resistance to, existing clinical cancer therapies, in particular other immunotherapy-based treatments,” said MSD.

According to Eric Rubin, vice president and therapeutic area head, oncology early-stage development, at Merck Research Laboratories, “the acquisition of IOmet is a further example of Merck’s commitment to fully realising the potential of this rapidly evolving field through our existing innovative portfolio as well as the acquisition of promising immunotherapeutic candidates”.

By Selina McKee

Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).